|
HK1223619A1
|
|
Phenyl amino pyrimidine compounds and uses thereof
|
|
AU2016202240A1
|
|
Inhibitors of kinase activity
|
|
AU2016200866A1
|
|
Phenyl amino pyrimidine compounds and uses thereof
|
|
AU2013273769A1
|
|
Inhibitors of Kinase Activity
|
|
AU2013263739A1
|
|
Thiopyrimidine-based Compounds And Uses Thereof
|
|
AU2013248233A1
|
|
N-containing heterocyclic compounds
|
|
US2014005161A1
|
|
Phenyl amino pyrimidine bicyclic compounds and uses thereof
|
|
AU2013201306A1
|
|
Phenyl Amino Pyrimidine Compounds and Uses Thereof
|
|
MX2013012785A
|
|
Multiple myeloma treatment.
|
|
WO2012071612A1
|
|
Treatment of jak2-mediated conditions
|
|
EP2215094A1
|
|
N-containing heterocyclic compounds
|
|
ME02378B
|
|
Phenyl amino pyrimidine compounds and uses thereof
|
|
EP2152701A1
|
|
Phenyl amino pyrimidine compounds and uses thereof
|
|
AU2007220047A1
|
|
Inhibition of JAK2 as a treatment of pulmonary arterial hypertension
|
|
AU2005203919A1
|
|
Selective kinase inhibitors
|
|
US2008194583A1
|
|
2-phenyl pyrimidines which are tubulin inhibitors
|
|
AU2004294355A1
|
|
Azole-based kinase inhibitors
|
|
EP1569907A1
|
|
Nicotinamide-based kinase inhibitors
|
|
AU2003291839A1
|
|
Nicotinamide-based kinase inhibitors
|
|
SI1569907T1
|
|
Nicotinamide-based kinase inhibitors
|
